Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

9%

1 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
10(90.9%)
Phase 3
1(9.1%)
11Total
N/A(10)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT05279534Not ApplicableTerminated

Efficacy and Safety of L. Plantarum and P. Acidilactici in Children With Upper Respiratory Tract Infections

Role: collaborator

NCT04037826Not ApplicableCompleted

L. Reuteri DSM 17938 and L. Reuteri ATCC PTA 6475 in Moderate to Severe Irritable Bowel in Adults

Role: lead

NCT04517422Not ApplicableCompleted

Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19

Role: collaborator

NCT04265716Not ApplicableUnknown

Topical L. Reuteri in Children With Atopic Dermatitis

Role: lead

NCT03375125Not ApplicableUnknown

L. Reuteri ATCC PTA 5289 + L. Reuteri DSM 17938 in Pregnant Women

Role: lead

NCT03360253Not ApplicableUnknown

Clinical Trial of L. Reuteri in Infantile Colic 2017

Role: lead

NCT03834415Not ApplicableCompleted

Lactobacillus Reuteri DSM17938 in C-Section Infants

Role: lead

NCT03377374Not ApplicableCompleted

L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis

Role: lead

NCT03362697Not ApplicableCompleted

Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women

Role: lead

NCT03372473Phase 3Completed

Montelukast and Loratadine in Children With Asthma

Role: lead

NCT03019172Not ApplicableCompleted

Clinical Trial of L. Reuteri in Urinary Tract Infections in Non Pregnant Women

Role: lead

All 11 trials loaded